Other Information.
+Added: Amendment to Fresenius Agreement
+Added: On August 7, 2024, we entered into Amendment No.3 (the “Amendment”) to the Fresenius Agreement with Fresenius Kabi.
+Added: The Amendment is effective as of July 31, 2024.
+Added: Pursuant to the Amendment, among other things, the term of the Agreement is extended until September 30, 2024 (or such later date as may be agreed upon between the parties).
+Added: The Amendment contains other customary terms applicable to the manufacture of therapeutics in the biotechnology industry.
+Added: The foregoing summary is not complete and is qualified in its entirety by reference to the Amendment, which will be filed as an exhibit in our subsequent periodic report to be filed under the Securities Exchange Act of 1934, as amended.
+Added: This disclosure is provided in this Part II, Item 5 in lieu of disclosure under Item 1.01 of Form 8-K.
Securities Trading Plans of Directors and Executive Officers
6 unchanged sentences
10.1+ Amendment No.2 to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product, dated April 1, 2024, by and between Aadi Bioscience, Inc.
−Removed: and Fresenius Kabi, LLC
−Removed: 31.1* Certification of Principal Executive Officer P ursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
+Added: and Fresenius Kabi, LLC (incorporated by reference to Exhibit 10.1 to the R egis trant 's Quarterly Report on Form 10-Q filed with the SEC on May 8, 2024).
+Added: 10.2*# Executive Employment Agreement, dated August 15, 2022, by and between the Company and Bryan E.
+Added: 10.3*# Amended and Restated Outside Director Compensation Plan.
+Added: 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
13 unchanged sentences
+ Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+Added: # Indicates a management contract or compensatory plan, contract or arrangement.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AADI BIOSCIENCE, INC.
−Removed: Lennon, Ph.D.
−Removed: Chief Executive Officer and President
−Removed: (Principal Executive Officer)
+Added: August 7, 2024
+Added: /s/ Scott Giacobello
+Added: Scott Giacobello
+Added: Chief Financial Officer
+Added: (Principal Financial Officer and Duly Authorized Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.